AstraZeneca: lackluster results matter less than upcoming trial outcome

2 February 2017
astrazeneca-large

Shares in AstraZeneca (LSE: AZN) fell around 1.5% this morning as the company provided cautious 2017 guidance as part of its full year and fourth quarter financial results statement.

For the fourth quarter, revenues were down 13% from the same period in 2015 at $5.6 billion, net (generally accepted accounting principles: GAAP) profits stood at $1.8 billion and the earnings per share (EPS) figure was $1.46.

For the year as a whole, revenues were down 7% at $23 billion. EPS increased 24% to $2.77, reflecting in part a revaluation of acquisition-related liabilities. Net profits for the year were $3.5 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical